US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
US6696407B1
(en)
|
1997-03-21 |
2004-02-24 |
The Regents Of The University Of California |
Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
|
GB9726339D0
(en)
|
1997-12-13 |
1998-02-11 |
Zeneca Ltd |
Human-derived tissue-specific potassium channel
|
SE9801474D0
(sv)
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
US6077851A
(en)
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
RS51019B
(sr)
|
1999-10-25 |
2010-10-31 |
Active Biotech Ab. |
Lekovi za lečenje malignih tumora
|
US6852323B2
(en)
|
2000-07-21 |
2005-02-08 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
ES2282667T3
(es)
*
|
2002-06-25 |
2007-10-16 |
Merck Frosst Canada Ltd. |
Inhibidores de pde4 8-(biaril)quinolinas.
|
US20070292461A1
(en)
|
2003-08-04 |
2007-12-20 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
CA2529873A1
(en)
|
2003-06-25 |
2005-01-06 |
Elan Pharmaceuticals, Inc. |
Methods and compositions for treating rheumatoid arthritis
|
US8795693B2
(en)
|
2003-08-04 |
2014-08-05 |
Foamix Ltd. |
Compositions with modulating agents
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
WO2005097162A2
(en)
|
2004-04-01 |
2005-10-20 |
Elan Pharmaceuticals, Inc. |
Steroid sparing agents and their use
|
WO2006029036A2
(en)
|
2004-09-02 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
US7560100B2
(en)
|
2004-09-09 |
2009-07-14 |
Yeda Research And Development Co., Ltd. |
Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
|
US20060205822A1
(en)
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
AU2006204699B2
(en)
|
2005-01-13 |
2012-04-26 |
Sirtris Pharmaceuticals, Inc. |
Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
|
CA2613678A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
NZ597082A
(en)
|
2005-10-13 |
2013-11-29 |
Human Genome Sciences Inc |
Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
EP1937642B1
(en)
|
2005-10-19 |
2014-09-10 |
Teva Pharmaceutical Industries Ltd |
Crystals of laquinimod sodium, and process for the manufacture thereof
|
AU2006307939B2
(en)
|
2005-10-26 |
2012-03-29 |
Merck Serono Sa |
Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
|
US20080108641A1
(en)
|
2006-02-08 |
2008-05-08 |
Ajami Alfred M |
Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
|
US8367629B2
(en)
|
2006-02-14 |
2013-02-05 |
Noxxon Pharma Ag |
MCP-1 binding nucleic acids and use thereof
|
WO2007100763A2
(en)
*
|
2006-02-28 |
2007-09-07 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
LT2676967T
(lt)
|
2006-02-28 |
2019-09-10 |
Biogen Ma Inc. |
Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
|
WO2007103112A2
(en)
|
2006-03-03 |
2007-09-13 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
RU2008137765A
(ru)
|
2006-03-16 |
2010-04-27 |
Генентек, Инк. (Us) |
Способы лечения волчанки с помощью антител к cd4
|
EP2010214A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
EA018031B1
(ru)
|
2006-06-12 |
2013-05-30 |
Тева Фармасьютикал Индастриз, Лтд. |
Стабильные препараты лаквинимода
|
CA2657716A1
(en)
|
2006-07-17 |
2008-01-24 |
Novartis Ag |
Cholanic acid amides
|
EP1886996A1
(en)
|
2006-08-10 |
2008-02-13 |
Ferrer Internacional, S.A. |
1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
|
EP2056818B1
(en)
|
2006-08-11 |
2011-05-25 |
The Johns Hopkins University |
Compositions and methods for neuroprotection
|
PL2056807T3
(pl)
|
2006-08-17 |
2013-02-28 |
Univ Chicago |
Leczenie chorób zakaźnych
|
WO2008085484A2
(en)
|
2006-12-28 |
2008-07-17 |
Jacobus Pharmaceutical Company, Inc. |
Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
|
CA2693697C
(en)
|
2007-07-11 |
2017-07-25 |
Medicinova, Inc. |
Treatment of progressive neurodegenerative disease with ibudilast
|
WO2009053070A1
(en)
|
2007-10-23 |
2009-04-30 |
Schwarz Pharma Ag |
Compounds for treating demyelination conditions
|
WO2009082471A1
(en)
|
2007-12-20 |
2009-07-02 |
Teva Pharmaceutical Industries, Ltd. |
Stable laquinimod preparations
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
MX2011002033A
(es)
|
2008-09-03 |
2011-05-02 |
Teva Pharma |
2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基-雜環化合物
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
WO2010147665A1
(en)
|
2009-06-19 |
2010-12-23 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with laquinimod
|
US8598203B2
(en)
*
|
2009-07-30 |
2013-12-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of Crohn's disease with laquinimod
|
PL3064206T3
(pl)
|
2009-08-10 |
2020-02-28 |
Active Biotech Ab |
Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
|
DE102010026879A1
(de)
*
|
2010-02-11 |
2011-08-11 |
AMW GmbH, 83627 |
Transdermales System mit Immunmodulator
|
BR112012021905A2
(pt)
|
2010-03-03 |
2015-09-29 |
Teva Pharma |
tratamento de nefrite lúpica usando laquinimod
|
CA2791709A1
(en)
|
2010-03-03 |
2011-09-09 |
Teva Pharmaceutical Industries Ltd. |
Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
|
PE20130496A1
(es)
|
2010-03-03 |
2013-05-08 |
Teva Pharma |
Tratamiento de artritis por lupus usando laquinimod
|
BR112013000607A2
(pt)
|
2010-07-09 |
2016-06-28 |
Teva Pharma |
5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações
|
PE20130396A1
(es)
*
|
2010-07-09 |
2013-04-19 |
Teva Pharma |
N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
|
EP2648732A4
(en)
|
2010-12-07 |
2014-04-30 |
Teva Pharma |
USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS
|
ES2602794T3
(es)
|
2011-03-31 |
2017-02-22 |
Pfizer Inc |
Piridinonas bicíclicas novedosas
|
EP2736336A4
(en)
|
2011-07-28 |
2015-03-04 |
Teva Pharma |
TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND INTERFERON-BETA
|
AU2012286699A1
(en)
|
2011-07-28 |
2014-03-13 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
|
MX2014004420A
(es)
|
2011-10-12 |
2014-07-09 |
Teva Pharma |
Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
|
AU2013221304B2
(en)
|
2012-02-16 |
2017-12-21 |
Teva Pharmaceutical Industries Ltd. |
N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
AR090885A1
(es)
|
2012-05-02 |
2014-12-10 |
Teva Pharma |
Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
|
TW201350467A
(zh)
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺
|
TW201400117A
(zh)
|
2012-06-05 |
2014-01-01 |
Teva Pharma |
使用拉喹莫德治療眼發炎疾病
|
WO2014004733A1
(en)
|
2012-06-26 |
2014-01-03 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型1(cb1)媒介之疾病之拉喹莫德(laquinimod)
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
|
KR20150080509A
(ko)
|
2012-10-12 |
2015-07-09 |
테바 파마슈티컬 인더스트리즈 리미티드 |
다발성 경화증에서 시상 손상 감소를 위한 라퀴니모드
|
EA201590788A1
(ru)
|
2012-11-07 |
2015-12-30 |
Тева Фармасьютикал Индастриз Лтд. |
Аминные соли лахинимода
|
KR20150119227A
(ko)
|
2013-02-15 |
2015-10-23 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
|
JP2016514162A
(ja)
|
2013-03-14 |
2016-05-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラキニモドナトリウムの結晶およびその製造のための改善された方法
|
EP2968203A1
(en)
|
2013-03-14 |
2016-01-20 |
Teva Pharmaceutical Industries Ltd. |
Transdermal formulations of laquinimod
|
WO2015109083A1
(en)
*
|
2014-01-17 |
2015-07-23 |
Teva Pharmaceutical Industries Ltd. |
Treatment of crohn's disease using low doses of laquinimod
|